This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar
by Zacks Equity Research
Novartis' (NVS) Sandoz broadens its biosimilar portfolio with Tyruko's approval, a biosimilar of the multiple sclerosis drug Tysabri in the EU.
Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study
by Zacks Equity Research
Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors study.
Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies
by Zacks Equity Research
Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.
FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease
by Zacks Equity Research
Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.
Novartis (NVS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Novartis (NVS) closed the most recent trading day at $101.14, moving -0.93% from the previous trading session.
Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study
by Zacks Equity Research
Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
by Zacks Equity Research
The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
by Zacks Equity Research
The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.
Novartis' (NVS) Shareholders Approve Sandoz Separation
by Zacks Equity Research
Novartis' (NVS) shareholders vote in favor of the 100% spin-off of Sandoz into a new publicly traded standalone company.
AbbVie's (ABBV) Skyrizi Crohn's Disease Study Meets Goals
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week 24 and superiority of endoscopic remission at week 48 versus J&J's Stelara in a head-to-head study.
Novartis' (NVS) Sandoz Gets Rights for Stelara Biosimilar
by Zacks Equity Research
Novartis (NVS) announces an agreement with Samsung Bioepis for exclusive rights to commercialize the biosimilar of Stelara in Europe and North America. The company discontinues the development of GT005 in geographic atrophy.
NVS vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Novartis (NVS) Stock Moves -0.2%: What You Should Know
by Zacks Equity Research
Novartis (NVS) closed the most recent trading day at $97.89, moving -0.2% from the previous trading session.
Here's Why Novartis (NVS) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Top Research Reports for Berkshire Hathaway, Adobe & Alibaba
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Adobe Inc. (ADBE) and Alibaba Group Holding Limited (BABA).
Novartis (NVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novartis (NVS) closed at $101.91 in the latest trading session, marking a -1.33% move from the prior day.
Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns
by Zacks Equity Research
Following the label expansion, Roche's (RHHBY) Evrysdi is now approved to treat people of all ages with SMA in the European Union.
10 Drugs Selected for Medicare Price Reduction
by Zacks Equity Research
10 Drugs Selected for Medicare Price Reduction
Medicare Drugs Targeted Under Inflation Reduction Act
by Mark Vickery
Last year, these 10 drugs made up $50 billion, about 20%, of Medicare part D costs.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca
by Zacks Equity Research
Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.
AbbVie (ABBV) Seeks Approval for Skyrizi for Ulcerative Colitis
by Zacks Equity Research
AbbVie's (ABBV) regulatory applications filed to the FDA and the EMA seeking approval for Skyrizi for ulcerative colitis are based on data from two phase III studies.
Novartis (NVS) Announces Positive Long-Term Data on Leqvio
by Zacks Equity Research
Novartis (NVS) Leqvio shows consistent efficacy and safety beyond six years in patients with ASCVD.
Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar
by Zacks Equity Research
Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.
Oncology Market's Huge Potential Puts These Stocks in Focus
by Sanghamitra Saha
The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.